HMB and Resistance Training After 50: The Evidence

HMB looks hard to justify as an add-on to resistance training for most adults over 50. The newest and most comprehensive meta-analysis found effects near zero for muscle mass and strength: standardized mean differences of 0.05 and 0.04, respectively. Those estimates are statistically compatible with small harm, no effect, or a trivial benefit—not the sort of result that earns a permanent line item in a supplement budget.

That conclusion applies to community-dwelling older adults who are already resistance training. It does not settle HMB's value during hospitalization, after surgery, or in people with diagnosed sarcopenia. Those are different clinical settings, with different physiology and much less certain evidence.

What the largest recent analysis found

Wang et al.'s 2026 meta-analysis pooled 13 randomized controlled trials involving 561 adults aged 50 and older. Each trial compared resistance training plus HMB with resistance training alone or a control condition. For muscle mass, the pooled standardized mean difference was 0.05 (95% CI, −0.10 to 0.20). The authors treated 0.20 as the lower boundary of a small body-composition effect, and the point estimate fell far below it.

The strength result was similarly unconvincing: SMD 0.04 (95% CI, −0.72 to 0.63). The confidence interval is wide, so it does not prove that every person receives zero benefit. It does show that the available trials cannot distinguish an average benefit from no benefit. Strength results also varied substantially between studies, making the pooled average less stable than the body-composition estimates.

Fat mass produced the one result worth examining closely: SMD 0.24 (95% CI, −0.01 to 0.49). It narrowly missed conventional statistical significance because the confidence interval crossed zero. Even if the estimate reflected a real effect, it would not explain why HMB failed to improve muscle mass or strength, and HMB's proposed biology does not establish a separate fat-loss mechanism. It is a lead for more research, not a reason to take HMB for body composition.

Body-composition heterogeneity was low, and the authors found no publication bias by funnel plot. Those checks do not make a null result definitive, but they make it harder to dismiss as a statistical accident.

For a healthy, community-dwelling adult over 50 who lifts weights, the best pooled estimate says HMB adds little or nothing to training for muscle mass or strength.

This is a pattern, not one disappointing review

The 2026 analysis agrees with several earlier high-level reviews. A 2025 systematic review and meta-analysis by García-Alonso et al., focused on muscle quality, body composition, and physical function in older adults using HMB alongside resistance training, also found no compelling benefit signal. A 2021 meta-analysis by Lin et al. judged the evidence for HMB and lean body mass in older adults weak. Then a 2022 umbrella review by Phillips et al., which assessed prior systematic reviews, reached the same broad conclusion for aging populations.

These reviews overlap in parts of the underlying literature, so they are not four wholly independent experiments. Still, they examine the question through different searches and outcome frames across five years. None identifies a reliable, clinically meaningful increment from adding HMB to resistance training in the general older-adult population.

Why the mechanism has not translated

HMB is a metabolite of leucine. Its proposed actions include reducing proteasomal protein breakdown and possibly increasing mTORC1-related anabolic signaling. That makes the most biological sense when muscle breakdown is unusually high—not necessarily when a well-nourished person is already providing a strong anabolic signal through progressive resistance training.

Clinical trials offer a plausible, but incomplete, version of that story. In a 2022 randomized trial by Han et al., HMB plus resistance training showed a positive signal in older sarcopenic patients after hip replacement. A 2024 multicenter four-arm randomized trial by Wu et al. tested resistance training, HMB at 3 g/day, both interventions, or standard care in 112 medical ICU patients during hospitalization; this is another setting where severe illness and immobilization create extreme catabolic pressure.

Neither study overturns the community-dwelling meta-analysis because neither enrolled the same population or tested the same practical question. They do support a narrower hypothesis: HMB may have more value when illness, surgery, or immobilization accelerates muscle loss. That hypothesis still needs meta-analytic testing by catabolic status before it becomes a routine clinical recommendation.

The unresolved sarcopenia question

A 2023 double-blind, placebo-controlled randomized trial by Yang et al. studied older adults with diagnosed sarcopenia. It is the most relevant individual trial for the possibility that HMB helps a clinically defined subgroup rather than generally healthy older exercisers. A positive result in one small trial would be a real counterpoint, not something to wave away.

But an individual trial cannot establish that sarcopenia changes the average HMB response. The 2026 meta-analysis does not provide a pre-specified sarcopenia subgroup analysis in its available abstract, and no pooled analysis has established whether protein intake, baseline sarcopenia, HMB dose, or intervention duration identifies responders. Until then, HMB for diagnosed sarcopenia remains an individualized possibility, not a general evidence-based default.

Vitamin D is another untested modifier. A small 2022 randomized trial by Fairfield et al. examined HMB plus vitamin D3 in middle-aged women and raised the possibility that vitamin D status could affect response. Because it combined two interventions in a specific population, it cannot tell us whether vitamin D changes HMB's independent effect in older adults who train.

What to spend effort on instead

The HMB result does not mean nutrition is useless during resistance training. A 2021 systematic review and meta-analysis by Martin-Cantero et al. found protein adequacy to be a more consistent influence on muscle-mass outcomes in older adults than HMB. A 2024 network meta-analysis by Liao et al. found that protein supplements, especially whey and essential-amino-acid formulations, tended to rank more favorably than placebo for muscle-mass outcomes in older adults with sarcopenia who performed resistance training.

That does not supply a direct HMB-versus-creatine effect-size comparison. The available evidence does not include a dedicated creatine-monohydrate-plus-resistance-training meta-analysis in adults 50 and older that permits that calculation. Still, the practical hierarchy is reasonable: build a progressive training routine, meet protein needs with high-quality foods or supplements when needed, and view creatine as a better-supported candidate than HMB rather than as a mathematically proven substitute.

For someone trying to prevent sarcopenia at 65, the decision is fairly plain. HMB has not shown a meaningful average benefit on muscle mass, strength, or body composition when added to resistance training. Reserve it for a clinician-guided discussion if you are recovering from surgery, hospitalized, immobilized, or managing diagnosed sarcopenia after training and protein intake have been addressed. For everyone else, the evidence favors putting the money and attention into the basics that have not yet been optimized.